Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: Case report and review

World Journal of Surgical Oncology

Volumn 8, Issue , 2010, Pages

  Hecker, Andreas ^a   Hecker, Birgit ^a   Bassaly, Birgit ^a   Hirschburger, Markus ^a   Schwandner, Thilo ^a   Janßen, Hermann ^b   Padberg, Windried ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b Institute of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CASE REPORT; DUODENUM TUMOR; EMERGENCY SURGERY; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; LAPAROTOMY; OUTCOME ASSESSMENT; PANCREATICODUODENECTOMY; PREOPERATIVE TREATMENT; TUMOR LOCALIZATION; TUMOR REGRESSION; TUMOR VOLUME; UPPER GASTROINTESTINAL BLEEDING; ADJUVANT THERAPY; CHEMICALLY INDUCED DISORDER; GASTROINTESTINAL HEMORRHAGE; MIDDLE AGED; PREOPERATIVE CARE; TREATMENT OUTCOME;

DUODENAL NEOPLASMS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PIPERAZINES; PREOPERATIVE CARE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 77952853770     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-8-47     Document Type: Article

References (19)

1. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998, 152:1259-1269. 1858579, 9588894.
2. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999, 30:1213-1220. 10.1016/S0046-8177(99)90040-0, 10534170.
3. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002, 33:459-465. 10.1053/hupa.2002.123545, 12094370.
4. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127-1134. 10.1016/S0140-6736(04)17098-0, 15451219.
5. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421-1423. 10.1016/S0140-6736(01)06535-7, 11705489.
6. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480. 10.1056/NEJMoa020461, 12181401.
7. Katz SC, DeMatteo RP. Gastrointestinal stromal tumors and leiomyosarcomas. J Surg Oncol 2008, 97:350-359. 10.1002/jso.20970, 18286477.
8. Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009, 99:42-47. 10.1002/jso.21160, 2606912, 18942073.
9. Bechtold RE, Chen MY, Stanton CA, Savage PD, Levine EA. Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec. Abdom Imaging 2003, 28:808-814. 10.1007/s00261-003-0021-2, 14753595.
10. van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, Sciot R, Van Glabbeke M, Dimitrijevic S, Nielsen OS. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002, 38(Suppl 5):S83-87. 10.1016/S0959-8049(02)80608-6, 12528778.
11. Miettinen M, Kopczynski J, Makhlouf HR, Sarlomo-Rikala M, Gyorffy H, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 2003, 27:625-641. 10.1097/00000478-200305000-00006, 12717247.
12. Winfield RD, Hochwald SN, Vogel SB, Hemming AW, Liu C, Cance WG, Grobmyer SR. Presentation and management of gastrointestinal stromal tumors of the duodenum. Am Surg 2006, 72:719-722. discussion 722-713.
13. Goh BK, Chow PK, Kesavan S, Yap WM, Wong WK. Outcome after surgical treatment of suspected gastrointestinal stromal tumors involving the duodenum: is limited resection appropriate?. J Surg Oncol 2008, 97:388-391. 10.1002/jso.20954, 18163461.
14. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005, 29:52-68. 10.1097/01.pas.0000146010.92933.de, 15613856.
15. Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006, 30:477-489. 10.1097/00000478-200604000-00008, 16625094.
16. Yang WL, Yu JR, Wu YJ, Zhu KK, Ding W, Gao Y, Shen QY, Lv KZ, Zhang Q, Yang XJ. Duodenal gastrointestinal stromal tumor: Clinical, pathologic, immunohistochemical characteristics, and surgical prognosis. J Surg Oncol 2009,
17. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231:51-58. 10.1097/00000658-200001000-00008, 1420965, 10636102.
18. Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PC, Brown M, Bertulli R, Judson IR. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005, 23:5795-5804. 10.1200/JCO.2005.11.601, 16110036.
19. Kurihara N, Kikuchi K, Tanabe M, Kumamoto Y, Tsuyuki A, Fujishiro Y, Otani Y, Kubota T, Kumai K, Kitajima M. Partial resection of the second portion of the duodenum for gastrointestinal stromal tumor after effective transarterial embolization. Int J Clin Oncol 2005, 10:433-437. 10.1007/s10147-005-0503-z, 16369749.